Explorer les evidences

36 %In Kisumu, seroprevalence of anti-SARS-CoV-2 IgG was 36.0% (95% CI 28.2–44.4%) at the beginning of the study period.

KenyaCOVID-19publié 2022PLOS global public healtheurope_pmcdocument de 7 observationsDOI 10.1371/journal.pgph.0000883

288 patientsThe study included 288 patients with critical COVID-19 admitted to the Aga Khan University Hospital, Nairobi between 1st March 2020 and 31st December 2021.

KenyaCOVID-19observé 1st March 2020 to 31st December 2021publié 2024PloS onePubMeddocument de 18 observations

By May 2021 in three broadly representative populations of unvaccinated individuals in Kenya, seroprevalence of anti-SARS-CoV-2 IgG was 25–50%.

KenyaCOVID-19observé May 2021publié 2022PLOS global public healtheurope_pmcdocument de 7 observationsDOI 10.1371/journal.pgph.0000883

50 %The Alpha variant was detected in 50.0% of persons aged 31 to 45 years among SARS-CoV-2 cases in Laikipia county, Kenya.

KenyaCOVID-19observé 24th April to 31st December 2021publié 2023Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-Coeurope_pmcdocument de 10 observations

6 genomesAll six recovered SARS-CoV-2 genomes classified within the 501Y.V2 variant of concern (lineage B.1.351).

Kenya501Y.V2 variant of concern · COVID-19 · lineage B.1.351publié 2021Wellcome open researcheurope_pmcdocument de 3 observations

3,78 odds_ratioOmicron was associated with cough (odds ratio 3.78; 95% CI 1.1–16.74, p = 0.026) relative to other SARS-CoV-2 variants of concern in Laikipia county, Kenya.

KenyaCOVID-19observé 24th April to 31st December 2021publié 2023Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-Coeurope_pmcdocument de 10 observations

24,9 %Among 1,123 hospitalized COVID-19 patients in Kenya, 24.9% had severe disease.

KenyaCOVID-19publié 2025Global health actionPubMeddocument de 11 observations

38,9 %Among patients with underlying conditions in Kenya's hospitalized COVID-19 cohort, diabetes was present in 38.9%.

KenyaCOVID-19 · diabète (non précisé)publié 2025Global health actionPubMeddocument de 11 observations

92,7 %The Platelia Total Ab Assay and the Mount Sinai spike IgG ELISA showed a high qualitative agreement of 92.7% in detecting SARS-CoV-2 antibodies in a mother-infant cohort in Nairobi, Kenya.

KenyaCOVID-19observé May 2019 to December 2020publié 2023Journal of medical virologyPubMeddocument de 3 observations

78 introduction_eventsAt least 78 independent SARS-CoV-2 introduction events occurred in Seychelles between 14 March 2020 and 31 December 2021.

KenyaCOVID-19observé 2020-03-14 to 2021-12-31publié 2022Viruseseurope_pmcdocument de 3 observationsDOI 10.3390/v14061318

33 %Few participants had symptoms: 33% of infants experienced symptoms of SARS-CoV-2 infection.

KenyaCOVID-19observé between May 1, 2020-February 1, 2022publié 2023PloS onePubMeddocument de 8 observations

0,58 odds_ratioThe odds of survival from COVID-19 disease were lower among cases aged ≥60 years (odds ratio = 0.58, P = 0.034).

KenyaCOVID-19publié 2022Journal of global healthPubMeddocument de 24 observations

0,58 odds_ratioThe odds of survival from COVID-19 disease were lower among cases with underlying conditions (odds ratio = 0.58, P = 0.025).

KenyaCOVID-19publié 2022Journal of global healthPubMeddocument de 24 observations

3,35 odds_ratioThe odds of survival from COVID-19 disease were higher among transport sector employees (odds ratio = 3.35, P = 0.004).

KenyaCOVID-19publié 2022Journal of global healthPubMeddocument de 24 observations

9 941 patientsBetween July 2022 and October 2023, a total of 9941 patients with severe respiratory illness were enrolled, of whom 588 (5.9%) tested positive for SARS-CoV-2.

Kenya · MaliCOVID-19observé July 2022 to October 2023publié 2026VaccinePubMeddocument de 8 observations

0,973 RThe Platelia Total Ab Assay and the Mount Sinai spike IgG ELISA showed a strong correlation of antibody levels with R = 0.973 in repeated measures in a mother-infant cohort in Nairobi, Kenya.

KenyaCOVID-19observé May 2019 to December 2020publié 2023Journal of medical virologyPubMeddocument de 3 observations

44 %SARS-CoV-2 seropositivity was found in 44% of the 125 infants in Nairobi, Kenya.

KenyaCOVID-19observé between May 1, 2020-February 1, 2022publié 2023PloS onePubMeddocument de 8 observations

51,4 %The Omicron variant was detected in 51.4% of persons aged 16 to 30 years among SARS-CoV-2 cases in Laikipia county, Kenya.

KenyaCOVID-19observé 24th April to 31st December 2021publié 2023Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-Coeurope_pmcdocument de 10 observations

41,5 %If SARS-CoV-2 self-testing were available, 41.5% of participants would be very likely to use it.

KenyaCOVID-19observé August 2021publié 2022International journal of public healtheurope_pmcdocument de 6 observations

43 yearsThe median age of hospitalized SARS-CoV-2-infected patients was 43 years (IQR 30–53), and 505 (64%) were men.

KenyaCOVID-19publié 2022BMJ openPubMeddocument de 7 observations

Within a mother-infant cohort in Nairobi, Kenya, seroprevalence detected by either the Platelia Total Ab Assay or the Mount Sinai spike IgG ELISA closely resembled previously published seroprevalence estimates for Kenya during the sampling period from May 2019 to December 2020.

KenyaCOVID-19observé May 2019 to December 2020publié 2023Journal of medical virologyPubMeddocument de 3 observations

31,8 %Among 1893 cases with likely sources of exposure in Kenya, 601 (31.8%) were due to international travel.

KenyaCOVID-19publié 2022Journal of global healthPubMeddocument de 24 observations

Kenya detected the first case of COVID-19 on March 13, 2020.

KenyaCOVID-19observé March 13, 2020publié 2022Journal of global healthPubMeddocument de 24 observations

2,82 aORMortality during COVID-19 hospitalization was nearly threefold higher among patients with heart disease (adjusted odds ratio [aOR] 2.82).

KenyaCOVID-19 · heart diseasepublié 2025Global health actionPubMeddocument de 11 observations

10 days52 (7%) of hospitalized SARS-CoV-2-infected patients were ventilated for a mean of 10 days.

KenyaCOVID-19publié 2022BMJ openPubMeddocument de 7 observations